0.0701 USD
-0.02 (-26.21%)
At close: Nov 2, 2022
0.0533 USD
-0.02 (-23.97%)
After Hours: 11/2/2022, 8:00:01 PM
ChartMill assigns a Buy % Consensus number of 46% to PHAS. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 1.02. This target is 1355.06% above the current price.
- PHAS was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about PHAS.
- In the last month the buy percentage fell by 30 points. So the trust of analysts is decreasing.
- PHAS was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-10-24 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2022-09-28 | William Blair | Downgrade | Outperform -> Market Perform |
| 2022-09-28 | Needham | Downgrade | Buy -> Hold |
| 2022-08-15 | Needham | Maintains | Buy |
| 2021-06-17 | Needham | Maintains | Buy |
| 2021-03-16 | Needham | Maintains | Buy |
PHASEBIO PHARMACEUTICALS INC / PHAS FAQ
Can you provide the average price target for PHASEBIO PHARMACEUTICALS INC stock?
7 analysts have analysed PHAS and the average price target is 1.02 USD. This implies a price increase of 1355.06% is expected in the next year compared to the current price of 0.0701.
How do analysts rate PHASEBIO PHARMACEUTICALS INC (PHAS)?
The consensus rating for PHASEBIO PHARMACEUTICALS INC (PHAS) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.